News

NRx Pharmaceuticals Expands NRX-101 for Enhanced TMS Treatment

NRx Pharmaceuticals Expands NRX-101 for Enhanced TMS Treatment

NRx Pharmaceuticals Enhances NRX-101 Pipeline in Depression Treatment

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) recently made a significant leap in its clinical advancements by amending its Investigational New Drug filing for NRX-101, which comprises D-cycloserine and lurasidone. This new amendment emphasizes the combination's potential enhancement of Transcranial Magnetic Stimulation (TMS) therapy for individuals battling depression, particularly those experiencing suicidal ideation.

Association of D-Cycloserine with TMS

The application of low-dose D-cycloserine in conjunction with TMS has been shown to augment antidepressant effects and contribute to anti-suicidal responses, an important breakthrough for providing relief to patients in critical need. Patients will have access to this novel treatment strategy through both clinical trials and an Expanded Access protocol, reflecting the company's commitment to patient-oriented care.

Clinical Data Supporting Efficacy

In recent findings, researchers observed that subjects receiving D-cycloserine while undergoing TMS exhibited more than double the improvement in their depressive symptoms compared to those given a placebo. Data from the D-cycloserine group indicated an impressive clinical response of 75%, with 40% achieving full remission. This suggests a profound potential for D-cycloserine to elicit neuroplasticity, vital for addressing brain regions affected by depression.

Real-World Evidence to Support Findings

Another promising report revealed that real-world data presented using a modern Theta Burst TMS device paired with a streamlined treatment protocol—the one-day regimen—resulted in a remarkable 87% clinical response rate, with 72% achieving remission within six weeks. Such robust outcomes strengthen the case for integrating D-cycloserine with TMS in clinical practice.

Looking Towards the Future

The integration of D-cycloserine into standard TMS therapy could reshape treatment paradigms, particularly for individuals who do not respond favorably to current antidepressant medications like SSRIs. The anticipated response rates from TMS alongside D-cycloserine could surpass 80%, a stark contrast to the approximate 30% success rate reported with traditional antidepressants.

Development and Regulatory Path

NRx's formula for combining D-cycloserine with lurasidone was borne from the need to counteract the low-grade hallucinations sometimes induced by D-cycloserine alone, addressing vital contraindications previously associated with the drug. The company's proactive strategy includes forming partnerships with manufacturers of established TMS devices to facilitate a collaborative trial aimed at securing regulatory approval and subsequent labeling adjustments for TMS therapy.

Market Potential and Patient Access

In light of the growing demand for TMS therapy, projections indicate that over one million Americans could benefit from TMS treatments by an anticipated future date, which opens lucrative avenues for NRx-101. This substantial market could offer new hope to individuals suffering from depression and related disorders.

NRx Pharmaceuticals has published an Expanded Access policy for NRX-101, encouraging healthcare professionals to explore how this innovative treatment could aid their patients. Healthcare providers interested in this new treatment modality are encouraged to reach out for more information.

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. is dedicated to leveraging its NMDA platform in the development of therapeutics aimed at central nervous system disorders, including suicidal depression, PTSD, and chronic pain. They are also advancing other projects including NRX-100, a preservative-free intravenous ketamine treatment, which has recently received Fast Track Designation for suicidal ideation treatments.

Frequently Asked Questions

What is NRX-101?

NRX-101 is a combination of D-cycloserine and lurasidone designed to enhance TMS therapy for depression treatment.

How does D-cycloserine work with TMS?

D-cycloserine is believed to improve neuroplasticity, providing more effective relief when used alongside TMS.

What are the potential benefits of NRX-101?

It may significantly improve clinical response rates in depression therapy and reduce dependence on traditional antidepressants.

Is NRX-101 currently available to patients?

Access is available through clinical trials and NRx's Expanded Access protocols.

How does NRx Pharmaceuticals support patients?

NRx provides detailed information about NRX-101 through an Expanded Access policy for physicians to help patients access innovative treatment options.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Stardock Fences 7 Targets Messy Windows Desktops Everywhere

Updated Category News Views 112

A cluttered Windows desktop is a tiny tax on attention, and Stardock has spent three decades selling people a way around it. Fences 7, released November 18, 2026, is the latest swing: a Windows 11-focused update that combines cosmetic polish with a genuinely practical privacy feature. This is not grand enterprise software, and nobody should pretend a $10 desktop utility...

Continue Reading
Texas Restaurants Get a New Read on Customer Demand

Updated Category News Views 173

Texas restaurant owners are being handed a sharper flashlight, and frankly it is overdue. HundredX and the Texas Restaurant Association have launched a pilot that gives TRA members access to the HundredX Restaurant Insights Platform, aiming to bring customer and market intelligence to the independent operators and regional chains that usually cannot pay big-company prices...

Continue Reading
Cold-Season Cleaning Advice Has a Practical Catch!

Updated Category News Views 53

Remote Controls Are Nobody’s First Suspect A television remote can make the rounds all evening and never see a cloth, which is precisely why Maid Brigade’s cold-and-flu-season reminder lands as common sense rather than revelation. The Scottsdale cleaning company is telling households to look past the usual kitchen counter and bathroom sink routine. Fair enough. People...

Continue Reading
Fox Hill Steel Marks a Long Public-Building Road Ahead

Updated Category News Views 54

A signed steel beam is a fine civic moment, but it is not the finish line. Burlington’s new Fox Hill Elementary School has reached its topping-off milestone, with the structural steel now in place for a 91,000-square-foot, two-story facility intended to serve roughly 325 kindergarten-through-fifth-grade students. That is tangible progress, the sort nobody can fake with...

Continue Reading
Radiology Staffing Gap Deepens as Imaging Demand Rises

Updated Category News Views 112

An imaging order does not mean much if nobody is available to read it, and that plain operational fact sits at the center of Medicus Healthcare Solutions' 2026 report on the radiologist shortage. The report's projected gap of 2,450 full-time-equivalent radiologists in 2027 is troubling enough. Its estimate of a 4,130 FTE shortfall by 2032 is the part that should make...

Continue Reading
Fapon’s Enzyme Push Meets Diagnostics Reality at AMP

Updated Category News Views 110

Enzymes rarely get applause at industry meetings, but they can quietly decide whether a diagnostic workflow behaves or becomes a lab headache. Fapon used its AMP 2026 appearance in Seattle to make that unglamorous case: better enzyme design may help assays move faster and keep working when samples get messy. The company wrapped up the November 10–14 meeting after...

Continue Reading
Commodity Rout Tests a Market Already Short on Nerve

Updated Category News Views 24

Some weeks the tape merely wobbles; this one started throwing furniture. By midday Wednesday, traders were staring at sharp declines in gold, silver, crude and copper while the major equity benchmarks remained underwater for the week. That is an unpleasant combination. When growth-sensitive commodities and the usual hard-asset hiding places are all getting sold,...

Continue Reading
Pressure Injury Care Needs More Than Awareness Alone

Updated Category News Views 52

Wet skin does not care how polished the awareness campaign looks. That is the uncomfortable truth sitting underneath Worldwide Pressure Injury Prevention Day, the annual observance held on the third Thursday of November. Pressure injuries remain a stubborn problem across healthcare facilities and home care settings because prevention is not one tidy action; it is a chain...

Continue Reading
Cadence Marks $2.7 Million for St. Jude Family Care

Updated Category News Views 172

Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...

Continue Reading
Resolve Adds Cahaba in Birmingham Pain-Care Expansion

Updated Category News Views 198

Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...

Continue Reading

Top 5 Most Recently Viewed Articles

Strategies for Investing During Market Peaks Explained

Updated Category News Views 291

Understanding Market Behaviors: Peaks and Investment Strategies The stock market has a tendency to rise over time. Historically, whether viewed through six-month, one-year, or even five-year lenses, the S&P 500 has consistently produced positive returns. This pattern holds true even as the market reaches record highs, a phenomenon that has drawn attention from analysts....

Continue Reading
Holborn Assets Launches Innovative App for Wealth Management

Updated Category News Views 212

Holborn Assets Introduces a Cutting-Edge Financial App In a significant move that underscores its commitment to digital transformation, Holborn Assets has rolled out an innovative app aimed at optimizing wealth management for its clients. This comprehensive financial management solution is specifically designed to provide users with seamless access to their financial...

Continue Reading
Growth of Mobivity's Connected Rewards in the Retail Sector

Updated Category News Views 137

Enhancing Customer Engagement with Connected Rewards Mobivity Holdings Corp. (OTCQB: MFON) has recently witnessed a remarkable surge in its Connected Rewards technology adoption among convenience store retailers. This significant development highlights how effective customer engagement solutions can reshape the retail landscape, particularly during the recent quarter. A...

Continue Reading
Coherent Boosts Silicon Carbide Production for AI and Datacenters

Updated Category News Views 192

Coherent Enhances Its Silicon Carbide Platform Coherent Corp. (NYSE: COHR), a global leader in photonics, has recently made significant strides in its development of silicon carbide (SiC) technology to meet the growing thermal efficiency needs of artificial intelligence in datacenter infrastructures. This advancement represents a major milestone for the company in its...

Continue Reading
World Bank's Commitment to Bangladesh: Over $2 Billion for Reforms

Updated Category News Views 140

World Bank Commits Over $2 Billion to Bangladesh The World Bank has recently made a major announcement regarding financial support for Bangladesh, pledging more than $2 billion for the current fiscal year. This funding is designed to help accelerate ongoing reform efforts, improve response to natural disasters, and enhance healthcare services and air quality throughout...

Continue Reading